Compass Therapeutics publishes tovecimig trial results in JCO
What it means
- What to watch: Drugmakers live and die by pipelines — what is in late-stage trials matters more than this quarter's sales.
- How the stock is trading: $CMPX -5.05% in the latest session.
- Timing: It landed over the weekend, while the market was off the clock: the change beside it is Friday's, and Monday is the first session that could react. Market holidays are not detected.
Where the stock stands
$CMPX last traded at $0.76, -5.05% on the session. That puts it 89% shy of its 52-week high of $6.88 and 1.5% clear of its low of $0.75 — within a tenth of its 52-week low. Over the year it has ranged 817% from low to high: a very wide band — this one has spent the year on a roller coaster, and big swings are business as usual. These are latest-session quotes, not live prices — the live tape is on the $CMPX page.
How much coverage it is getting
In the last 30 days Wook has filed 1 story about $CMPX — 1 of them this week. At its 30-day pace you would expect about 0 a week, so this week is running well ahead of normal; the press has found a reason to keep writing. Across those stories the wording ran 0% bullish, 100% neutral and 0% bearish. This one reads neutral, so it sits squarely with the crowd. This is the only one from Investing.com; the rest came from other outlets. 12 of them are listed beside this one.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. On Wook's supply-chain scanner, Health Care reads calm today — no unusual stress in the filings and disclosures it watches. The scanner equivalent of a quiet night shift.
Coming up
$CMPX earnings in 11 days. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the next hard numbers on this company are almost here.
What to watch next
The $CMPX page has the full chart, the filings and the valuation model behind every figure here. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. Wook AI, above, can pull live figures and run the numbers on request — how far $CMPX is from its high, or how this week's coverage compares.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $CMPX. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.